Diels-Alder Adducts of Morphinan-6,8-Dienes and Their Transformations

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 May 14

PMID 35566212

Authors

Janos Marton

Aniko Fekete

Paul Cumming

Sandor Hosztafi

Pal Mikecz

Gjermund Henriksen

Affiliations

Soon will be listed here.

Abstract

6,14-ethenomorphinans are semisynthetic opiate derivatives containing an ethylene bridge between positions 6 and 14 in ring-C of the morphine skeleton that imparts a rigid molecular structure. These compounds represent an important family of opioid receptor ligands in which the 6,14-etheno bridged structural motif originates from a [4 + 2] cycloaddition of morphinan-6,8-dienes with dienophiles. Certain 6,14-ethenomorphinans having extremely high affinity for opioid receptors are often non-selective for opioid receptor subtypes, but this view is now undergoing some revision. The agonist 20-etorphine and 20-dihydroetorphine are several thousand times more potent analgesics than morphine, whereas diprenorphine is a high-affinity non-selective antagonist. The partial agonist buprenorphine is used as an analgesic in the management of post-operative pain or in substitution therapy for opiate addiction, sometimes in combination with the non-selective antagonist naloxone. In the context of the current opioid crisis, we communicated a summary of several decades of work toward generating opioid analgesics with lesser side effects or abuse potential. Our summary placed a focus on Diels-Alder reactions of morphinan-6,8-dienes and subsequent transformations of the cycloadducts. We also summarized the pharmacological aspects of radiolabeled 6,14-ethenomorphinans used in molecular imaging of opioid receptors.

References

Henriksen G, Willoch F . Imaging of opioid receptors in the central nervous system. Brain. 2007; 131(Pt 5):1171-96. PMC: 2367693. DOI: 10.1093/brain/awm255. View

Herz A, Hollt V . [Receptor occupation and pharmacological activity as demonstrated on opiates (author's transl)]. Arzneimittelforschung. 1977; 27(96):1865-7. View

Werner L, Machara A, Adams D, Cox D, Hudlicky T . Synthesis of buprenorphine from oripavine via N-demethylation of oripavine quaternary salts. J Org Chem. 2011; 76(11):4628-34. DOI: 10.1021/jo200567n. View

Li F, Yang B, Miller M, Zajicek J, Noll B, Mollmann U . Iminonitroso Diels-Alder reactions for efficient derivatization and functionalization of complex diene-containing natural products. Org Lett. 2007; 9(15):2923-6. DOI: 10.1021/ol071322b. View

Bentley K, Hardy D, Crocker H, Haddlesey D, Mayor P . Novel analgesics and molecular rearrangements in the morphine-thebaine group. VI. Base-catalyzed rearrangements in the 6,14-endo-ethenotetrahydrothebaine series. J Am Chem Soc. 1967; 89(13):3312-21. DOI: 10.1021/ja00989a035. View

Kling M, Carson R, Borg L, Zametkin A, Matochik J, SCHLUGER J . Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000; 295(3):1070-6. View

Hutchins C, Rapoport H . Analgesics of the orvinol type. 19-Deoxy and 6,20-epoxy derivatives. J Med Chem. 1984; 27(4):521-7. DOI: 10.1021/jm00370a015. View

Maat L, Woudenberg R, Meuzelaar G, Linders J . Chemistry of opium alkaloids. Part 44: synthesis and opioid receptor binding profile of substituted ethenoisomorphinans and ethenomorphinans. Bioorg Med Chem. 1999; 7(3):529-41. DOI: 10.1016/s0968-0896(98)00267-3. View

Wu H, Wacker D, Mileni M, Katritch V, Han G, Vardy E . Structure of the human κ-opioid receptor in complex with JDTic. Nature. 2012; 485(7398):327-32. PMC: 3356457. DOI: 10.1038/nature10939. View

10.

Karlsson H, Tuominen L, Tuulari J, Hirvonen J, Parkkola R, Helin S . Obesity is associated with decreased μ-opioid but unaltered dopamine D2 receptor availability in the brain. J Neurosci. 2015; 35(9):3959-65. PMC: 6605573. DOI: 10.1523/JNEUROSCI.4744-14.2015. View

11.

Ray S, Gupta H, Gupta Y . Up-regulation of mu-opioid receptors in the spinal cord of morphine-tolerant rats. J Biosci. 2004; 29(1):51-6. DOI: 10.1007/BF02702561. View

12.

Klein P, Nelson W, Yao Y, Simon E . Electrophilic alpha-methylene-gamma-lactone and isothiocyanate opioid ligands related to etorphine. J Med Chem. 1990; 33(8):2286-96. DOI: 10.1021/jm00170a038. View

13.

Lewis J, Rushworth W . Novel analgesics and molecular rearrangements in the morphine-thebaine group. XVII. Compounds related to the thebaine-maleic anhydride adduct. J Chem Soc Perkin 1. 1970; 4:560-4. DOI: 10.1039/j39700000560. View

14.

Lever J, Mazza S, Dannals R, Ravert H, Wilson A, Wagner Jr H . Facile synthesis of [11C]buprenorphine for positron emission tomographic studies of opioid receptors. Int J Rad Appl Instrum A. 1990; 41(8):745-52. DOI: 10.1016/0883-2889(90)90022-9. View

15.

Boura A, FITZGERALD A . The pharmacology of N-(cyclopropylmethyl)-19-isopentylnororvinol hydrochloride. A potent and long lasting central depressant. Br J Pharmacol Chemother. 1966; 26(2):307-21. PMC: 1510649. DOI: 10.1111/j.1476-5381.1966.tb01910.x. View

16.

TAKEMORI A, Hayashi G, Smits S . Studies on the quantitative antagonism of analgesics by naloxone and diprenorphine. Eur J Pharmacol. 1972; 20(1):85-92. DOI: 10.1016/0014-2999(72)90219-1. View

17.

Sipos A, Skaliczki T, Berenyi S, Antus S . Thiazole constrained analogues of the thevinones: synthesis and structure. Magn Reson Chem. 2009; 47(9):801-7. DOI: 10.1002/mrc.2447. View

18.

Manu P, Rogozea L, Shulman M . Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of Medicine. Am J Ther. 2022; 29(2):e193-e198. DOI: 10.1097/MJT.0000000000001478. View

19.

Dannals R, Ravert H, Frost J, Wilson A, Burns H, Wagner Jr H . Radiosynthesis of an opiate receptor binding radiotracer: [11C]carfentanil. Int J Appl Radiat Isot. 1985; 36(4):303-6. DOI: 10.1016/0020-708x(85)90089-4. View

20.

Husbands S, Breeden S, Grivas K, Lewis J . Ring constrained analogues of the orvinols: the furanomorphides. Bioorg Med Chem Lett. 1999; 9(6):831-4. DOI: 10.1016/s0960-894x(99)00085-2. View